ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer, Journal of Clinical Oncology, vol.24, issue.33, pp.5313-5327, 2006. ,
DOI : 10.1200/JCO.2006.08.2644
TNM classification of malignant tumors, 2002. ,
Colorectal cancer, The Lancet, vol.365, issue.9454, pp.153-165, 2005. ,
DOI : 10.1016/S0140-6736(05)17706-X
Tumor immunosurveillance in human cancers, Cancer and Metastasis Reviews, vol.9, issue.1, pp.5-12, 2011. ,
DOI : 10.1007/s10555-011-9270-7
Natural immunity to cancer in humans, Current Opinion in Immunology, vol.22, issue.2, pp.215-222, 2010. ,
DOI : 10.1016/j.coi.2010.02.006
Cancer Immunology, New England Journal of Medicine, vol.358, issue.25, pp.2704-2715, 2008. ,
DOI : 10.1056/NEJMra072739
Gene Signature in Melanoma Associated With Clinical Activity, The Cancer Journal, vol.16, issue.4, pp.399-403, 2010. ,
DOI : 10.1097/PPO.0b013e3181eacbd8
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome, Science, vol.313, issue.5795, pp.1960-1964, 2006. ,
DOI : 10.1126/science.1129139
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness, Cancer Res, vol.62, pp.3581-3586, 2002. ,
The Adaptive Immunologic Microenvironment in Colorectal Cancer: A Novel Perspective, Cancer Research, vol.67, issue.5, pp.1883-1886, 2007. ,
DOI : 10.1158/0008-5472.CAN-06-4806
Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction, Journal of Clinical Oncology, vol.29, issue.6, pp.610-618, 2011. ,
DOI : 10.1200/JCO.2010.30.5425
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer, New England Journal of Medicine, vol.353, issue.25, pp.2654-2666, 2005. ,
DOI : 10.1056/NEJMoa051424
In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.35, pp.5944-5951, 2009. ,
DOI : 10.1200/JCO.2008.19.6147
A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers", Journal of Translational Medicine, vol.6, issue.1, p.81, 2008. ,
DOI : 10.1186/1479-5876-6-81
Recommendations from the iSBTc-SITC/FDA, Immunotherapy Biomarkers. Clin Cancer Res, vol.17, pp.3064-3076, 2011. ,
Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology, Journal of Translational Medicine, vol.7, issue.1, p.45, 2009. ,
DOI : 10.1186/1479-5876-7-45
URL : https://hal.archives-ouvertes.fr/inserm-00585733
Immune infiltration in human tumors: a prognostic factor that should not be ignored, Oncogene, vol.173, issue.8, pp.1093-1102, 2010. ,
DOI : 10.1038/nrc1586
TNM Staging in Colorectal Cancer: T Is for T Cell and M Is for Memory, Journal of Clinical Oncology, vol.29, issue.6, pp.601-603, 2011. ,
DOI : 10.1200/JCO.2010.32.9078
: Function, Generation, and Maintenance, Annual Review of Immunology, vol.22, issue.1, pp.745-763, 2004. ,
DOI : 10.1146/annurev.immunol.22.012703.104702
An immunologic portrait of cancer, Journal of Translational Medicine, vol.9, issue.1, p.146, 2011. ,
DOI : 10.1158/1078-0432.CCR-08-3323
Defining the critical hurdles in cancer immunotherapy, Journal of Translational Medicine, vol.9, issue.1, p.214, 2011. ,
DOI : 10.1126/science.317.5840.966
URL : https://hal.archives-ouvertes.fr/inserm-00691923
Future perspectives in melanoma research. Meeting report from the " Melanoma Research: a bridge Naples- USA, p.32, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00834025